The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein

PLoS Pathogens

Volumn 8, Issue 5, 2012, Pages

  Beernink, Peter T ^a   Shaughnessy, Jutamas ^b   Pajon, Rolando ^a   Braga, Emily M ^a   Ram, Sanjay ^b   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIUM ANTIBODY; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; IMMUNOGLOBULIN G; MENINGOCOCCUS NATIVE OUTER MEMBRANE VESICLE VACCINE; MENINGOCOCCUS VACCINE; MUTANT PROTEIN; RECOMBINANT COMPLEMENT FACTOR H BINDING PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; COMPLEMENT FACTOR H, HUMAN; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; OUTER MEMBRANE PROTEIN;

ADSORPTION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MEMBRANE VESICLE; MOUSE; MUTANT; NEISSERIA MENINGITIDIS; NONHUMAN; PROTEIN BINDING; PROTEIN ENGINEERING; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENETICS; HUMAN; IMMUNOLOGY; PATHOGENICITY; SERUM BACTERICIDAL ANTIBODY ASSAY;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; FEMALE; HUMANS; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEISSERIA MENINGITIDIS; PROTEIN BINDING; RECOMBINANT PROTEINS; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 84863698711     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002688     Document Type: Article

References (43)

1. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, et al. (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 50: 184-191.
2. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, et al. (2007) A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 31: 27-36.
3. Hayrinen J, Jennings H, Raff HV, Rougon G, Hanai N, et al. (1995) Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 171: 1481-1490.
4. Finne J, Leinonen M, Makela PH, (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2: 355-357.
5. Trotter CL, Ramsay ME, (2007) Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31: 101-107.
6. Granoff DM, (2010) Review of meningococcal group B vaccines. Clin Infect Dis 50 (Suppl 2): S54-65.
7. Sadarangani M, Pollard AJ, (2010) Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 10: 112-124.
8. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
9. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
10. Snape MD, Dawson T, Oster P, Evans A, John TM, et al. (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29: e71-79.
11. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, et al. (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51: 1127-1137.
12. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, et al. (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28: 6086-6093.
13. Pinto VB, Moran EE, Cruz F, Wang XM, Fridman A, et al. (2011) An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups. Vaccine 29: 7752-7758.
14. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2011) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29: 1413-1420.
15. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
16. Granoff DM, Welsch JA, Ram S, (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77: 764-769.
17. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, et al. (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186: 3606-3614.
18. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM, (2011) Meningococcal factor h binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 5: e1302.
19. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, et al. (2011) Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29: 4728-4734.
20. Koeberling O, Delany I, Granoff DM, (2011) A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 18: 736-742.
21. Koeberling O, Giuntini S, Seubert A, Granoff DM, (2009) Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 16: 156-162.
22. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM, (2009) Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 199: 1360-1368.
23. Koeberling O, Seubert A, Granoff DM, (2008) Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198: 262-270.
24. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093-1096.
25. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, et al. (1991) Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14: 67-79.
26. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, et al. (2001) Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69: 5981-5990.
27. Steeghs L, Tommassen J, Leusen JH, van de Winkel JG, van der Ley P, (2004) Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res 10: 113-119.
28. Hou VC, Koeberling O, Welsch JA, Granoff DM, (2005) Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192: 580-590.
29. Giuntini S, Reason DC, Granoff DM, (2011) Complement-mediated bactericidal activity of anti-Factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79: 3751-3759.
30. Welsch JA, Rossi R, Comanducci M, Granoff DM, (2004) Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172: 5606-5615.
31. Rouppe van der Voort EM, Kuipers B, Brugghe HF, van Unen LM, Timmermans HA, et al. (1997) Epitope specificity of murine and human bactericidal antibodies against PorA P1.7,16 induced with experimental meningococcal group B vaccines. FEMS Immunol Med Microbiol 17: 139-148.
32. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM, (2002) Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70: 6021-6031.
33. Beernink PT, Shaughnessy J, Ram S, Granoff DM, (2010) Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol 17: 1074-1078.
34. Vu DM, Wong TT, Granoff DM, (2011) Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine 29: 1968-1973.
35. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, et al. (2010) The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6: e1001027.
36. Pajon R, Beernink PT, Harrison LH, Granoff DM, (2010) Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28: 2122-2129.
37. Dunphy KY, Beernink PT, Brogioni B, Granoff DM, (2011) Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun 79: 353-359.
38. Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie JE 3rd, et al. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28: 5057-5067.
39. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, et al. (2011) Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 3: 91ra62.
40. Beernink PT, Granoff DM, (2008) Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 76: 2568-2575.
41. Meri S, Jordens M, Jarva H, (2008) Microbial complement inhibitors as vaccines. Vaccine 26 (Suppl 8): I113-117.
42. Herzenberg LA, Tung J, Moore WA, Parks DR, (2006) Interpreting flow cytometry data: a guide for the perplexed. Nat Immunol 7: 681-685.
43. Sacchi CT, Lemos AP, Brandt ME, Whitney AM, Melles CE, et al. (1998) Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 5: 845-855.